CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Non-Viral Genetic Modification Using The 4D-Nucleofector LV Unit In CGT

  This paper underscores the 4D-Nucleofector® LV Unit as a pivotal tool for translating genetic modification technologies into scalable, safe, and effective therapeutic solutions.

• Inside The Payer Perspective On Cell And Gene Therapy Coverage

  Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.

• Single-Use Assembly Capabilities To Keep Pace With Biopharma Dynamics

  Discover how a vendor-independent partner assists global life science companies and CDMOs with innovative single-use technologies to mitigate risks and ensure uninterrupted manufacturing.

• Sample Clean-Up After N-Linked Glycan Release And Labeling

  Glycan profiling starts with effective clean-up. See how comparable recovery across key labeled glycans and sialylated glycan groups can support confident analysis while helping labs manage costs.

• How Automated NGS Solutions Advance Rare Disease Research

  See how a unified NGS workflow is helping a major pediatric genetics lab boost efficiency, manage growing sample volumes, and accelerate insights into rare diseases through streamlined automation.

• Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer

  Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.

• Accelerated LVV Manufacturing Enabled By Platform Excellence

  Discover how a manufacturing platform enabled the rapid production of lentiviral vector in eight months. Learn the strategy used to balance speed, risk mitigation, and the highest quality standards.

• Streamline Antibody Analysis For Faster Protein Characterization

  Strengthen your antibody characterization. Explore approaches for improving sizing accuracy, resolving heterogeneity, and generating reproducible data across demanding biopharmaceutical workflows.

• Confident Sialic Acid Identification With MS/MS

  Traditional mass spectrometry left uncertainty around potentially immunogenic glycans. Learn how a biologics developer achieved regulatory-ready clarity.

• Study: Ensuring Homogeneity In Biopharmaceutical Aliquotation

  Tired of manual manipulation risks in biopharmaceuticals? Discover how automated homogenization ensures consistent cell counts and concentration levels, improving patient safety and process reproducibility.